Welcome to AstraZeneca United States
Beginning its journey in 1953, AstraZeneca became one of the first pharmaceutical companies operating in the United States
Latest News from AstraZeneca US
LYNPARZA® (olaparib) reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial
AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced results from the OlympiA Phase III trial showed LYNPARZA® (olaparib) demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
AstraZeneca ASCO 2021 data support ambition to revolutionize cancer outcomes by treating earlier and transforming the patient experience
LYNPARZA is the first targeted medicine to show clinical benefit in the adjuvant setting for patients with germline BRCA-mutated high-risk HER2-negative early breast cancer
CALQUENCE shows sustained four-year clinical benefit in 1st-line chronic lymphocytic leukemia and lower atrial fibrillation rates in previously treated patients vs. ibrutinib
IMFINZI five-year data represent longest-ever survival reported in a Phase III immunotherapy trial in unresectable Stage III lung cancer
New FASENRA® data from the MELTEMI extension trial confirm long-term safety and efficacy in severe eosinophilic asthma for up to five years
Data confirm FASENRA’s well-established safety profile consistent with previous Phase III trials
At least 75% of FASENRA-treated patients with elevated blood eosinophil levels had zero exacerbations each year of the open-label period
Latest AZ&You Blog Articles
If you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.